P12: Benchmark dose for 3-monochloro-propane-1,2-diol (3-MCPD) in rat 2-year study

Chronic exposure guideline levels for the public are generally based on doses that produce no effects, following a NOAEL/LOAEL approach. Benchmark dose (BMD) approach devised by Crump (1982) may use to determine critical effect dose that are more or less conservative than the NOAEL/LOAEL approach. In this study, the use of the BMD as an alternative to a NOAEL approach was investigated as a mean to improve current risk assessment values of 3-monochloro-propane-1,2-diol (3-MCPD). We reviewed for the critical toxicological endpoints of 3-MCPD, namely nephropathy, tubular hyperplasia and tubule adenoma identified from the two available critical studies. Using the USEPA BMD software, considering available dichotomous models, we calculated BMDs of 3-MCPD, and their lower confidence limits (BMDLs) at response levels of 10%. The BMDs and BMDLs for the three end points were estimated using the Weibull, Probit, Linear, and Log-logistic models for each end point. All models passed the x 2 test statistics ( p